ChemicalBook > CAS DataBase List > JNJ-38158471

JNJ-38158471

JNJ-38158471 Structure
JNJ-38158471
  • CAS No.951151-97-6
  • Chemical Name:JNJ-38158471
  • CBNumber:CB92621141
  • Molecular Formula:C15H17ClN6O3
  • Formula Weight:364.79
  • MOL File:951151-97-6.mol
JNJ-38158471 Property
  • Density 1.42±0.1 g/cm3(Predicted)
  • storage temp. Store at -20°C
  • solubility DMSO: 30 mg/mL (82.24 mM);Ethanol: Insoluble
  • pka 13.06±0.70(Predicted)
  • form Solid
  • color Gray to brown
  • Water Solubility Water: Insoluble
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H315-H319-H335
  • Precautionary statements P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501

JNJ-38158471 Chemical Properties,Usage,Production

  • Uses JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC50s of 180 and 500 nM, respectively[1].
  • in vivo

    JNJ-38158471 (10 or 100 mg/kg; p.o.; once-daily) inhibits VEGF-induced corneal neovascularization[1].
    JNJ-38158471 (10-200 mg/kg; p.o.) inhibits the growth of human tumor xenografts in a dose-dependent manner in both A431 and HCT116 models. JNJ-38158471 treatment is well tolerated, following continuous administration for 24 days, body weights were comparable with control animals[1].
    JNJ-38158471 (100 mg/kg; p.o.; once-daily) treatment shows statistically signi?cant activity compare with vehicle treat animals. The body weights of both JNJ-38158471-treated and vehicle-treated groups were comparable at study end[1].

    Animal Model:Female C57BL/6J mice are implanted with rhVEGF165[1]
    Dosage:10 or 100 mg/kg
    Administration:Daily oral administration for 6 days
    Result:Caused a marked and apparently dose-dependent inhibition of VEGF-dependent blood vessel formation (100 mg/kg, resulted in 83% inhibition; 10 mg/kg, resulted in 15% inhibition).
    Animal Model:Female athymic nude mice; 5-6 weeks; implanted subcutaneously human colorectal carcinoma cells (HCT116) or human epidermoid carcinoma cells (A431)[1]
    Dosage:10, 50, 100, 200 mg/kg
    Administration:Oral administration for 35 days
    Result:Achieved optimum ef?cacy with the dose from 100 to 200 mg/kg daily.
    Animal Model:Female athymic nude mice; 5-6 weeks; implanted subcutaneously human skin melanoma cells (A375)[1]
    Dosage:100 mg/kg
    Administration:Once-daily oral administration for 28 days
    Result:Inhibited 90% growth of tumor with daily doses of 100 mg/kg.
    Animal Model:Female C57BL/6J-Apc Min mice; 5 weeks of age[1]
    Dosage:100 mg/kg
    Administration:Once-daily oral administration for two weeks
    Result:Inhibited polyp formation in the transgenic APC min-mouse model.
  • IC 50 VEGFR-2: 40 nM (IC50); RET: 180 nM (IC50); c-Kit: 500 nM (IC50)
  • References [1] Kenneth RL, et, al. A Highly Selective, Orally Bioavailable, Vascular Endothelial Growth Factor receptor-2 Tyrosine Kinase Inhibitor Has Potent Activity in Vitro and in Vivo. Angiogenesis. 2009; 12(3): 287-96. DOI:10.1007/s10456-009-9151-7
JNJ-38158471 Preparation Products And Raw materials
Raw materials
Preparation Products
JNJ-38158471 Suppliers
Global(45)Suppliers
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58
  • Supplier：
    Aladdin Scientific
  • Tel：
  • Email：tp@aladdinsci.com
  • Country：United States
  • ProdList：57505
  • Advantage：58
  • Supplier： SYN|thesis med chem P/L
  • Tel：+86-021-50720296
  • Email：service@synkinase.com
  • Country：China
  • ProdList：266
  • Advantage：58
JNJ-38158471 Spectrum
951151-97-6, JNJ-38158471Related Search:
  • 抑制剂
  • 药靶配体
  • C15H17ClN6O3
  • 化合物CS-2660 (JNJ-38158471),10 MM DMSO 溶液
  • 1-(4-((6-氨基-5-((甲氧基亚氨基)甲基)嘧啶-4-基)氧基)-2-氯苯基)-3-乙基脲
  • 化合物CS-2660 (JNJ-38158471)
  • 951151-97-6
  • JNJ-38158471, 10 mM in DMSO
  • Urea, N-[4-[[6-amino-5-[(methoxyimino)methyl]-4-pyrimidinyl]oxy]-2-chlorophenyl]-N'-ethyl-
  • VEGFR-2,JNJ 38158471,VEGFR,cancer,SCFR,malignancies,JNJ38158471,Kit,c-Kit,CD117,RET,Vascular endothelial growth factor receptor,JNJ-38158471,inhibit,Inhibitor
  • CS-2660 (JNJ-38158471)
  • 1-(4-((6-Amino-5-((methoxyimino)methyl)pyrimidin-4-yl)oxy)-2-chlorophenyl)-3-ethylurea
  • 1-[4-[6-amino-5-[(E)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea
  • CS-2660
  • (E)-1-(4-((6-Amino-5-((methoxyimino)methyl)pyrimidin-4-yl)oxy)-2-chlorophenyl)-3-ethylurea
  • JNJ-38158471

Home

My